Accueil・Liste d'Actions・CRISPR Therapeutics AG

CRISPR Therapeutics AG

Ouvert

SecteurSoins de santé

52.85 7.09

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

48.94

Max

52.47

Chiffres clés
By Trading Economics
Revenu	7.7M -123M
Ventes	594K 1.5M
BPA	-1.28
Marge bénéficiaire	-8,431.481
Employés	393
EBITDA	31M -118M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+50.21% upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-315M 4.6B
Ouverture précédente	45.76
Clôture précédente	52.85

Sentiment de l'Actualité

By Acuity

24%

76%

67 / 340 Classement par Healthcare

CRISPR Therapeutics AG Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 août 2026, 23:02 UTC

Social Media

News

CRISPR Therapeutics reported second-quarter revenue of $10.18 million, exceeding expectations. Shares are trading higher in after-market hours following the earnings report.

31 juil. 2026, 23:06 UTC

Shares of CRISPR Therapeutics AG are trading higher in after-market hours. The stock remains near the lower end of its one-month trading range.

30 juil. 2026, 23:02 UTC

News

CRISPR Therapeutics shares are lower in after-market hours amid broader market weakness, despite analysts projecting revenue growth and a price target of $83.53.

29 juil. 2026, 22:01 UTC

CRISPR Therapeutics AG shares are lower in after-market trading amid broader market declines driven by geopolitical tensions and caution ahead of the Fed's interest rate decision.

28 juil. 2026, 23:01 UTC

Correlated Moves

CRISPR Therapeutics AG shares are lower in after-market trading, reflecting broader market trends and a decline in the Russell 2000 Index.

27 juil. 2026, 19:07 UTC

CRISPR Therapeutics AG shares are higher today, gaining since Friday's close. The stock peaked earlier in the session before pulling back.

23 juil. 2026, 10:36 UTC

CRISPR Therapeutics AG shares are roughly flat in pre-market hours, with no specific company news identified. The stock remains near the lower end of its trading range.

22 juil. 2026, 23:06 UTC

CRISPR Therapeutics AG shares are trading higher in after-market hours, though they remain below their 20-day moving average and near the lower end of their one-month range.

21 juil. 2026, 19:26 UTC

News

Correlated Moves

CRISPR Therapeutics AG shares are higher today, buoyed by a strong gene-editing pipeline and positive analyst sentiment regarding its lead asset, CASGEVY.

20 juil. 2026, 23:22 UTC

CRISPR Therapeutics AG is trading higher in after-market hours, despite broader market declines linked to rising treasury yields. No specific news was identified.

Comparaison

Variation de prix

CRISPR Therapeutics AG prévision

Objectif de Prix

By TipRanks

50.21% hausse

Prévisions sur 12 Mois

Moyen 74.46 USD 50.21%

Haut 110 USD

Bas 45 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

67 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.